Home blood pressure monitoring (HBPM) is increasingly being recognized as an accurate adjunct to clinic blood pressure measurement for the diagnosis and management of hypertension. We discussed the HOPE Asia Network’s recently published consensus recommendations on HBPM with lead author, Prof. Sungha Park.
Click here to view the interview video with one of the authors - Professor Sungha Park
In an effort to better understand hypertension subtypes – including morning and white-coat hypertension – in Asian patients, the HOPE Asia Network has initiated the Asia BP@Home study across 12 countries and regions. We discussed the study’s design and objectives with lead investigator, Prof. Kazuomi Kario.
Click here to view the interview video with lead investigator - Professor Kazuomi Kario
Data presented at the 13th APCH, and recently published in the Journal of Clinical Hypertension, highlighted the current challenges of hypertension management in Asia and how home blood pressure monitoring may improve cardiovascular outcomes. We discussed the paper with lead author, Prof. Yook-Chin Chia.
Results from the ASCOT-LLA study suggest that patient reports of muscle-related adverse events were more common when patients knew they were being treated with a statin. We discussed this phenomenon, known as the ‘nocebo effect’, with senior investigator, Prof. Peter Sever.
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.